The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

Results from the national "Urgent Conversations" survey, announced today by Eli Lilly and Company (NYSE: LLY), found that ...

Johnson & Johnson's immunology superstar Stelara and oncology blockbuster Darzalex have long been among the company's top ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...

Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease: Indianapolis Tuesday, October 15, 2024, 18:00 Hrs [IST] Eli Lilly a ...

Cobenfy's journey from the lab through regulatory approval is a case study in how America's world-class scientists work to ...

Eli Lilly announced data demonstrating more patients with moderately to severely active Crohn’s disease treated with ...

The firm reported growth slightly ahead of our expectations.

On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...